Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI
May 2, 2024 4:48 PM EDTEvercore ISI analyst Vijay Kumar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $14.50 (from $15.00) while maintaining a In Line rating.
The analyst comments "NVCR reported headline revs of $139 MM, up +13% y/y (vs -11% comp) with total revs coming in slightly above ST. Total revs incl ~$4.2 MM from prior period claims in U.S., ex which magnitude of the Beat was ~3%. Active patients and TRx both grew... More
